David Hyman
大卫·海曼
MD
Chief Medical Officer, Lilly Oncology; Former Chief of Early Drug Development, MSK礼来肿瘤学首席医疗官；前纪念斯隆-凯特琳早期药物开发部主任
👥Biography 个人简介
David Hyman, MD is a leading oncologist who pioneered histology-agnostic and basket trial designs at MSK and played a central role in the NCI-MATCH master protocol. He has led landmark trials for NTRK, HER2, and BRAF inhibitors across tumor types, fundamentally reshaping oncology trial paradigms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Basket Trials and Histology-Agnostic Oncology
Designed and led landmark basket trials demonstrating that targeted agents can be approved based on molecular alterations rather than tumor histology, establishing the regulatory paradigm for tissue-agnostic approvals.
NCI-MATCH Master Protocol
Central contributor to the NCI-MATCH (Molecular Analysis for Therapy Choice) trial, the largest precision oncology master protocol evaluating targeted therapies across multiple biomarker-defined tumor types.
Representative Works 代表性著作
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
New England Journal of Medicine (2015)
Landmark basket trial establishing histology-agnostic activity of BRAF inhibition across multiple tumor types harboring BRAF V600 mutations.
Larotrectinib in TRK Fusion–Positive Cancers
New England Journal of Medicine (2018)
Pivotal basket trial of TRK inhibitor across 17 tumor types leading to the first tissue-agnostic FDA approval based solely on molecular alteration.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 大卫·海曼 的研究动态
Follow David Hyman's research updates
留下邮箱，当我们发布与 David Hyman（Eli Lilly and Company (formerly Memorial Sloan Kettering Cancer Center)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment